Emicizumab prophylaxis beyond clinical trials: a multicenter, prospective real-world study of pediatric hemophilia patients with and without inhibitors.

Eur J Pediatr · 2026 · PMC13070065 · PMID 41964698

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP < 0.001actually significant

Within-group changes from baseline to 12 months were highly significant for both subgroups (Wilcoxon P < 0.001 for each).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.